What research says about blood-based orthobiologics

What to know about the different results

Researchers call shots made from body material orthobiologics, while PRP is the blood-based kind. PRP stands for platelet-rich plasma.

Some knee studies found less soreness or easier movement after PRP than after gel or cortisone shots, while other studies found no useful difference from plain salt water at all. So the research doesn't support one result for every joint.

The studies don't give one dependable amount of relief to expect. They also don't show that paying more brings a better result.

What to ask about the blood preparation

For PRP, blood is drawn and spun until platelets gather in part of the liquid. Clinics can gather different amounts or leave different blood parts in that liquid.

Those differences matter because the shots used in two studies may not be alike. Ask exactly how your blood will be prepared and why that version suits what the exam found.

Ask how long the relief lasted and whether some patients got none. Your X-ray, daily needs, health, and budget still belong in the decision.

What to do when ordinary care hasn't helped

QC Kinetix offers concentrated PRP, which uses the same blood draw and spinning process with more platelets gathered in the liquid. It's one of the clinic's regenerative treatments, meaning non-surgical shots made from body material.

A medical provider, the clinician responsible for your exam, can compare it with exercise, physical therapy, or surgery. Ask about the possible relief and the limits.

Bring an old X-ray if you have one, and ask for plain answers. If the blood preparation isn't clear, have the clinician explain it again.

Sources

1. A network meta-analysis of 43 trials (5,554 patients) reached the OPPOSITE ranking to the more recent orthobiologic-favourable reviews: steroids ranked most likely to be effective for pain and function, with adipose MSC and multiple PRP ranked LEAST likely; single PRP, multiple PRP and adipose MSC did not produce a relevant reduction in pain or improvement in function versus placebo. The authors noted treatment-effect differences were small and potentially not clinically meaningful either way.

   Han SB, et al. — Intra-Articular Injections of Hyaluronic Acid or Steroids Associated With Better Outcomes Than Platelet-Rich Plasma, Adipose Mesenchymal Stromal Cells, or Placebo in Knee Osteoarthritis: A Network Meta-analysis.. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2020.03.041.

2. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-rich and leukocyte-poor PRP significantly superior to placebo and to hyaluronic acid for function at 6-12 months (MD vs placebo -13.20 and -10.54 respectively). LP-PRP ranked highest (P-score 0.96) but the DIRECT comparison between the two formulations showed no statistically significant difference, and the authors concluded there is insufficient evidence to recommend one PRP formulation over the other.

   Xu B, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2026. DOI: 10.1186/s13018-026-06689-4.

3. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.

4. A double-blind randomized trial allocated 192 patients with KL 1-3 knee OA to three weekly injections of leukocyte-RICH or leukocyte-POOR PRP (mean leukocyte concentration 7,991 x10^6/L vs 0.1 x10^6/L). No difference was found in any clinical score at 2, 6 or 12 months (IKDC improved 45.6 to 60.7 vs 46.8 to 62.9; P=.626). Mild adverse events were numerically more frequent with leukocyte-rich PRP (12.2% vs 4.7%) but not significantly so.

   Di Martino A, et al. — Leukocyte-Rich versus Leukocyte-Poor Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Trial.. American Journal of Sports Medicine, 2022. DOI: 10.1177/03635465211064303.

5. A 2026 systematic review of leukocyte-rich versus leukocyte-poor PRP for osteoarthritis concluded the current evidence is insufficient to determine whether adding leukocytes provides any clinical benefit, that results generally show no significant difference between the two, and that there is no conclusive evidence local reactions are caused by leukocytes specifically.

   Martin-Vega M, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma for Osteoarthritis: A systematic review.. Regenerative Therapy, 2026. DOI: 10.1016/j.reth.2026.101078.

6. The BMJ meta-analysis of viscosupplementation pooled 169 trials (21,163 participants) and found clear evidence of small-study effects and publication bias. In the prespecified main analysis of 24 LARGE placebo-controlled trials (8,997 participants) hyaluronic acid reduced pain by SMD -0.08 (95% CI -0.15 to -0.02), equivalent to 2.0 mm on a 100 mm scale - far below the -0.37 minimal important difference - and trial sequential analysis showed there has been CONCLUSIVE evidence of clinical equivalence to placebo since 2009. Fifteen large trials showed a significantly higher risk of serious adverse events (RR 1.49).

   Pereira TV, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

7. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.